Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694386 | 1.00 | PNP (0.54) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL655858 | 0.89 | PNP (0.65) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL655857 | 0.89 | PNP (0.65) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL21779018 | 0.88 | PNP (0.55) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL114652 | 0.88 | PNP (0.55) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL195548 | 0.88 | PNP (0.55) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL3868526 | 0.87 | PNP (0.54) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL18723297 | 0.87 | PNP (0.54) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL14543297 | 0.87 | PNP (0.54) | PNPCYP3A4MAPTPOLBLMNA | |
| SCHEMBL657361 | 0.87 | PNP (0.54) | PNPCYP3A4MAPTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2707483-B1 | METHODS AND MATERIALS FOR NUCLEIC ACID MANIPULATION | RWTH AACHEN UNIV (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | UNIVERSITE LIBRE DE BEUXELLES (BE) | 2012-05-17 | — | — | US | disclosed |
| WO-2010136546-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | Université Libre de Bruxelles (BE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122948-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | MPO, SERPINB1, MAOA | PNP 857/4885CYP3A4 452/4885MAPT 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.